logo
Merck to Present New Clinical and Outcomes Research Data at The American Thoracic Society's (ATS) 2025 International Conference Demonstrating Commitment to Advancing Research in Pulmonary Arterial Hypertension

Merck to Present New Clinical and Outcomes Research Data at The American Thoracic Society's (ATS) 2025 International Conference Demonstrating Commitment to Advancing Research in Pulmonary Arterial Hypertension

Business Wire16-05-2025

BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new clinical and outcomes research data on pulmonary arterial hypertension (PAH) to be presented at the American Thoracic Society's (ATS) 2025 International Conference in San Francisco from May 16-21. Data from nine presentations demonstrate Merck's commitment to advancing research for patients with this disease.
Merck will present pooled data from participants who have completed the PULSAR, SPECTRA, or STELLAR studies and have continued in the ongoing open-label extension study, SOTERIA, evaluating the long-term safety, tolerability and efficacy of WINREVAIR™ (sotatercept-csrk) when added to background therapy for the treatment of PAH. These results represent the largest analysis of WINREVAIR to date.
"The results from this pooled analysis add to the growing body of evidence for WINREVAIR,' said Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories. 'We remain confident in the long-term potential for WINREVAIR for patients with PAH and look forward to sharing findings as we continue to evaluate WINREVAIR."
Merck will also present an overall survival analysis for WINREVAIR leveraging data from the pivotal Phase 3 study, STELLAR, and interim data from participants who have continued in the ongoing open-label SOTERIA study, as well as additional outcomes research on the burden and impact of PAH in various patient populations.
Details on Merck abstracts at ATS:
PAH
Long-term safety and exposure-adjusted incidence rates of adverse events from pooled sotatercept studies (PULSAR, SPECTRA, STELLAR, and SOTERIA). I. Preston.
Session B96 Crossing the Golden Gate Bridge: clinical trials, targeted therapies and novel approaches in pulmonary arterial hypertension on Monday, May 19, 5:15 – 7:15 p.m. ET/2:15 – 4:15 p.m. PT
Overall survival of patients on sotatercept: an analysis of STELLAR and SOTERIA trials. T. Thakur.
Session B96 Crossing the Golden Gate Bridge: clinical trials, targeted therapies and novel approaches in pulmonary arterial hypertension on Monday, May 19, 5:15 – 7:15 p.m. ET/2:15 – 4:15 p.m. PT
Long-term safety of MK-5475 in pulmonary arterial hypertension (PAH): Results from the phase 2 INSIGNIA-PAH extension period. P. Hassoun.
Poster Board #505; D28 Fisherman's Wharf: Clinical and epidemiological insights into pulmonary hypertension: trends, treatments, and outcomes on Wednesday, May 21, 11:15 a.m. – 1:15 p.m. ET/8:15 – 10:15 a.m. PT
Quantifying the impact of pulmonary arterial hypertension (PAH) on health-related quality of life (HRQOL), work productivity, and economic stability for patients and their caregivers. H. Black.
Poster Board #1018; B23 Diffuse lung disease and pulmonary hypertension: clinical perspectives on Monday, May 19, 12:15 –2:15 p.m. ET/9:15 –11:15 a.m. PT
Comparing the burden of pulmonary arterial hypertension (PAH) among women across regions: a patient survey. T. Thakur.
Poster Board #1021; B23 Diffuse lung disease and pulmonary hypertension: clinical perspectives on Monday, May 19, 12:15 – 2:15 p.m. ET/9:15 – 11:15 a.m. PT
Perceptions, attitudes and behaviors among women of childbearing and childrearing age with pulmonary arterial hypertension. T. Thakur.
Poster Board #1020; B23 Diffuse lung disease and pulmonary hypertension: clinical perspectives on Monday, May 19, 12:15 –2:15 p.m. ET/9:15 – 11:15 a.m. PT
The impact of cardiopulmonary comorbidities on the economic burden and mortality of pulmonary arterial hypertension in the United States. H. Black.
Poster Board #P253; A36 Pulmonary hypertension patient experience, health services and outcomes on Sunday, May 18, 12:15 – 7:15 p.m. ET/9:15 a.m. – 4:15 p.m. PT
Caregiver network and caregiving needs in women with pulmonary arterial hypertension (PAH). T. Thakur.
Poster Board #P254; A36 Pulmonary hypertension patient experience, health services and outcomes on Sunday, May 18, 12:15 – 7:15 p.m. ET/9:15 a.m. – 4:15 p.m. PT
Acute inpatient utilization among Medicaid patients treated for pulmonary arterial hypertension. A. Watanabe.
Poster Board #P251; A36 Pulmonary hypertension patient experience, health services and outcomes on Sunday, May 18, 12:15 – 7:15 p.m. ET/9:15 a.m. – 4:15 p.m. PT
Expand
About WINREVAIR ™ (sotatercept-csrk) for injection, for subcutaneous use, 45 mg, 60 mg
WINREVAIR is FDA-approved for the treatment of adults with pulmonary arterial hypertension (PAH, WHO Group 1) to increase exercise capacity, improve WHO functional class (FC) and reduce the risk of clinical worsening events. WINREVAIR is the first activin signaling inhibitor therapy approved to treat PAH. WINREVAIR improves the balance between pro-proliferative and anti-proliferative signaling to modulate vascular proliferation. In preclinical models, WINREVAIR induced cellular changes that were associated with thinner vessel walls, partial reversal of right ventricular remodeling, and improved hemodynamics.
WINREVAIR is the subject of a licensing agreement with Bristol Myers Squibb.
Selected Safety Information for WINREVAIR in the U.S.
WINREVAIR may increase hemoglobin (Hgb). Severe erythrocytosis may increase the risk of thromboembolic events or hyperviscosity syndrome. Monitor Hgb before each dose for the first 5 doses, or longer if values are unstable, and periodically thereafter, to determine if dose adjustments are required.
WINREVAIR may decrease platelet count. Severe thrombocytopenia may increase the risk of bleeding. Thrombocytopenia occurred more frequently in patients also receiving prostacyclin infusion. Do not initiate treatment if platelet count is <50,000/mm3. Monitor platelets before each dose for the first 5 doses, or longer if values are unstable, and periodically thereafter to determine whether dose adjustments are required.
In clinical studies, serious bleeding (e.g., gastrointestinal, intracranial hemorrhage) was reported in 4% of patients taking WINREVAIR and 1% of patients taking placebo. Patients with serious bleeding were more likely to be on prostacyclin background therapy and/or antithrombotic agents, or have low platelet counts. Advise patients about signs and symptoms of blood loss. Do not administer WINREVAIR if the patient is experiencing serious bleeding.
WINREVAIR may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use an effective method of contraception during treatment with WINREVAIR and for at least 4 months after the final dose. Pregnancy testing is recommended for females of reproductive potential before starting WINREVAIR treatment.
Based on findings in animals, WINREVAIR may impair female and male fertility. Advise patients on the potential effects on fertility.
The most common adverse reactions occurring in the phase 3 clinical trial (≥10% for WINREVAIR and at least 5% more than placebo) were headache (24.5% vs 17.5%), epistaxis (22.1% vs 1.9%), rash (20.2% vs 8.1%), telangiectasia (16.6% vs 4.4%), diarrhea (15.3% vs 10.0%), dizziness (14.7% vs 6.2%), and erythema (13.5% vs 3.1%).
Because of the potential for serious adverse reactions in the breastfed child, advise patients that breastfeeding is not recommended during treatment with WINREVAIR, and for 4 months after the final dose.
About PAH
Pulmonary arterial hypertension (PAH) is a rare, progressive and life-threatening blood vessel disorder characterized by the constriction of small pulmonary arteries and elevated blood pressure in the pulmonary circulation. Approximately 40,000 people in the U.S. are living with PAH. The disease progresses rapidly for many patients. PAH results in significant strain on the heart, leading to limited physical activity, heart failure and reduced life expectancy. The five-year mortality rate for patients with PAH is approximately 43%.
About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the 'company') includes 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2024 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).
http://www.merck.com/product/usa/pi_circulars/w/winrevair/winrevair_pi.pdf, Patient Information for WINREVAIR at , and Instructions for Use for WINREVAIR (1-vial kit, 2-vial kit) at https://www.merck.com/product/usa/pi_circulars/w/winrevair/winrevair_ifu_1-vial_2-vial_kits.pdf.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

BIOSeedin Innovation Partnering Conference 2025: Spotlight on China's Biopharma Trailblazers and Global Collaboration
BIOSeedin Innovation Partnering Conference 2025: Spotlight on China's Biopharma Trailblazers and Global Collaboration

Yahoo

time35 minutes ago

  • Yahoo

BIOSeedin Innovation Partnering Conference 2025: Spotlight on China's Biopharma Trailblazers and Global Collaboration

China's influential innovative drug asset cooperation platform NEWARK, Del., June 9, 2025 /PRNewswire/ -- BIOSeedin Innovation Partnering Conference (BIOS), established in 2021, has quickly become one of the most prestigious biopharmaceutical partnering events in APAC. Hosted annually by bioSeedin, BIOS has attracted cutting-edge biotech startups and top investment firms globally. It serves as a crucial platform for fostering collaboration between China's biopharma sector and global markets, facilitating partnerships, therapeutic asset licensing, and investment networking. The 5th annual BIOSeedin Innovation Partnering Conference solidified its role as a nexus for global biopharma innovation, attracting more than 2,000 registrants from 10 countries. Senior executives and investors dominated the audience, with 61.66% holding C-suite, BD, or investment roles. The event facilitated 7,275 meeting requests. Confirmed deals across oncology, rare diseases, and next-gen modalities. MNCs including Merck & Co., Pfizer and Bayer emerged as top targets, with key accounts receiving over 50 meeting requests each. Key Insights from BIOS Discussions Dr. Yi Zhu, Founder and CSO of Biokin Pharma, framed China as a "translational research powerhouse", uniquely positioned to de-risk high-impact modalities. "Our cost-efficient clinical execution enables rapid validation of novel ADCs and gene-editing platforms," he noted, citing Biokin's Phase II PD-1xLAG-3 bispecific antibody as evidence of China's ability to advance complex biologics. His call for investors to prioritize high-risk, high-reward assets resonated across sessions, particularly as Chinese startups now contribute 38% of global ADC patents. John Zhu, CEO of DualityBio, challenged conventional innovation metrics during a standing-room-only session. "True differentiation isn't about target novelty but biomarker-driven clinical value," he asserted, showcasing DualityBio's tumor-activated ADC linker technology. His critique of "therapeutic crowding" aligned with investor interest in China's precision medicine pipelines, particularly in NSCLC and triple-negative breast cancer. Dr. Zhang Lianshan, EVP of Hengrui Pharma, grounded discussions in localization imperatives. "Globalization starts with domestic validation," he emphasized, detailing Hengrui's strategy to leverage China's 140 million cancer patient registry for accelerated oncology trials. His case study on a Claudin 18.2-targeted therapy — now in global Phase III — highlighted China's evolving role from fast follower to protocol co-designer. Jacky Jiang, BD Head at CSPC Pharma, outlined a pragmatic blueprint for strategic asset curation. "Align R&D with unmet needs, technical strengths, and M&A agility," he advised, referencing CSPC's recent acquisition of a CRISPR-Cas12Max delivery platform. His prediction that non-viral gene therapies will dominate rare disease investments by 2026 drew vigorous investor follow-ups. 40 companies gave roadshows and brought abundant assets The BIOSeedin 2025 roadshow spotlighted China's accelerating leadership in next-generation therapies, with 40% of showcased assets featuring breakthrough modalities like Phase II PD-1xLAG-3 bispecifics for NSCLC, preclinical Claudin 18.2xCD3 T-cell engagers, and tumor microenvironment-activated ADC linkers — technologies where Chinese firms now hold 32% of global patents. Rare disease innovations included non-viral CRISPR-Cas12Max therapies for retinal disorders (90% primate model efficacy) and Duchenne MD gene therapies, while metabolic/CNS advances featured dual GLP-1/GIP agonists outperforming competitors in weight loss trials and tau-targeting Alzheimer's mAbs. With 50% of programs in Phase I/II (including 10 breakthrough-designated assets) and two Phase III candidates nearing 2026 NDAs — a bispecific NSCLC antibody leveraging China's genomic databases and a non-opioid TRPV1-ATP analgesic — the portfolio underscores China's evolution from fast follower to global innovator, combining cost-efficient development with patient-centric therapeutic engineering. Building on this year's success, BIOSeedin 2026 will expand its global footprint with dedicated tracks for European and North American attendees. As Dr. Zhu Yi concluded, "China's biotech sector is not just catching up — it's redefining innovation. We invite global partners to join this journey, where collaboration transcends borders and accelerates patient-centric breakthroughs." Join us next year to explore investment opportunities, forge transformative partnerships, and shape the future of biopharma innovation. View original content: SOURCE bioSeedin Sign in to access your portfolio

When is Apple's WWDC 2025 event? Start time, rumors, more
When is Apple's WWDC 2025 event? Start time, rumors, more

USA Today

time11 hours ago

  • USA Today

When is Apple's WWDC 2025 event? Start time, rumors, more

When is Apple's WWDC 2025 event? Start time, rumors, more Show Caption Hide Caption How to use AI rewriting tools Artificial Intelligence can instantly proofread your writing and make suggestions to tweak the tone of a message, paper or presentation. Problem Solved Apple's Worldwide Developers Conference is less than a day away, though it appears that the event will see a restrained rollout compared to the AI extravaganza held a year ago. The week-long event will kick off with a keynote address on Monday, June 9, and run through Friday, June 13. There will be more than 100 technical sessions for developers, as well as group and one-on-one lab sessions, Apple announced in a news release. USA TODAY will provide live coverage of Monday's keynote, along with the latest updates on the company reveals. Here's what you need to know before Apple's Worldwide Developers Conference 2025. How to watch WWDC 2025 The keynote for WWDC 2025 takes place at Apple Park in Cupertino, California, on June 9 at 1 p.m. ET/10 a.m. PT and be followed by a "Platforms State of the Union." The keynote is set to be streamed on Apple TV, the Apple YouTube page and at USA TODAY will also provide live coverage. What might be revealed at WWDC 2025? Bloomberg's Mark Gurman reported that Apple is preparing a modest rollout of artificial intelligence features, targeting WWDC 2026 to make a larger splash. Gurman wrote in the Power On newsletter that the most significant AI announcement this year will be the opening of Apple's Foundation Models to third-party developers. He noted that the move is being made in hope of spurring the creation of new AI features and apps to help Apple catch up in the artificial intelligence market. Gurman also reported that Apple appears set to add a centralized gaming app in the next iOS update. He indicates the app will be preinstalled with the update and will be a place for users to launch games, find new titles, view leaderboards and communicate with other players. "The new app will serve as a Game Center replacement, and is more ambitious," Gurman wrote. "But it's unlikely to shake up the industry." iOS naming system to change with update: Reports Apple appears set to change the naming system for iOS on Monday, according to Gurman. The company will move from numbering operating system updates sequentially to numbering them by year in a manner similar to the way car models are identified. Under the new system, the Monday update will be iOS 26 instead of iOS 19. Gurman also reported that the Mac operating system will be named Tahoe after the Californian forest.

Johnson & Johnson, Merck lead 14 NJ companies on 2025 Fortune 500 list
Johnson & Johnson, Merck lead 14 NJ companies on 2025 Fortune 500 list

Yahoo

time15 hours ago

  • Yahoo

Johnson & Johnson, Merck lead 14 NJ companies on 2025 Fortune 500 list

The numbers are in. has released it's yearly rankings of the biggest U.S. companies that made the most money for 2025 — The Fortune 500. This year, 14 New-Jersey-based businesses made the list. The digital media outlet survey analyzed data from companies that are incorporated in the U.S., operate in the U.S. and file financial statements with a government agency. Fortune 500 companies represent two-thirds of the U.S. GDP with $18.8 trillion in revenues, $1.7 trillion in profits and $43 trillion in market value (as of March 28, 2024), and they employ 31 million people worldwide, the report stated. There are 14 companies headquarted in the Garden State that made the list. Below are their ranks. No. 42: Johnson and Johnson No. 67: Merck No. 81: Prudential Financial No. 98: Bristol-Myers Squibb No. 112: PBF Energy No. 211: Becton Dickinson No. 213: Cognizant Technology No. 228: Automatic Data Processing No. 345: Avis Budget No. 359: Public Service Enterprise Group No. 404: Burlington Stores No. 419: Campbell's No. 423: Quest Diagnostics No. 445: Zoetis Walmart Amazon Apple UnitedHealth Group Berkshire Hathaway CVS Health Exxon Mobil Alphabet McKesson Cencora This article originally appeared on Asbury Park Press: 2025 Fortune 500: NJ's top corporations revealed

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store